Premium
cDNA microarray to determine early and late gene expression in dopaminergic neurodegeneration
Author(s) -
Weinreb O.,
Mandel S.,
Youdim M. B. H.
Publication year - 2003
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1046/j.1471-4159.85.s2.8_2.x
Subject(s) - neurodegeneration , neuroprotection , mptp , oxidative stress , dopaminergic , gene expression , biology , parkinson's disease , neurotoxin , nitric oxide synthase , rasagiline , pharmacology , dopamine , neuroscience , medicine , nitric oxide , biochemistry , gene , disease , endocrinology
Although the etiology of neurodegeneration in Parkinson's disease is not known, biochemical evidence support the roles of iron, oxidative stress and inflammatory processes leading to neurodegeneration. We have investigated in vivo and in vitro , the alterations in gene expression, using the human and mice cDNA expression array membranes where several gene pathways can be analyzed at once, confirmed with quantitative RT‐PCR and protein analyses. Chronic treatment of mice with the neurotoxin MPTP caused alterations of 57 different genes involved in oxidative stress, inflammatory processes, glutamate, nitric oxides synthase and cell cycle. Pretreatment of mice with neuroprotective antiparkinsonian drugs, e.g. Rasagiline, R‐apomorphine and green tea polyphenol, EGCG, prevented the increase or decrease of most of the genes induced neuroprotection of dopamine neurons. Our studies provide new prospects to identify various mechanisms of neurodegeneration and neuroprotection, and discovery of effective neuroprotective antiparkinsonian drugs.